Advanced search
Publication Cover
HIV Clinical Trials Volume 18, 2017 - Issue 4
Submit an article Journal homepage
283
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128)

Rima KulkarniClinical Virology, Gilead Sciences, Inc., Foster City, CA, USACorrespondence[email protected]
,
Sally L. HodderHealth Sciences Center, West Virginia Clinical and Translational Science InstituteMorgantown, WV, USAORCID Iconhttp://orcid.org/0000-0002-0728-5550
ORCID Icon,
Huyen CaoClinical Research, Gilead Sciences, Inc., Foster City, CA, USA
,
Silvia ChangClinical Virology, Gilead Sciences, Inc., Foster City, CA, USA
,
Michael D. MillerClinical Virology, Gilead Sciences, Inc., Foster City, CA, USA
&
Kirsten L. WhiteClinical Virology, Gilead Sciences, Inc., Foster City, CA, USA
Pages 164-173 | Published online: 11 Sep 2017

References

  • Joint United Nations Programme on HIV/AIDS (UNAIDS). Global aids update 2016. Available at: https://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016. May 31, 2016.
  • Sherman LA, Temple R, Merkatz RB. Women in clinical trials: an FDA perspective. Science. 1995;269(5225): 793–795.10.1126/science.7638593
  • Bennett JC. Inclusion of women in clinical trials -- policies for population subgroups. N Engl J Med. 1993;329(4): 288–292.10.1056/NEJM199307223290428
  • Soon GG, Min M, Struble KA, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000–2008). AIDS Patient Care and STDs. 2012;26(8): 444–453.10.1089/apc.2011.0278
  • Hodder S, Arasteh K, De Wet J, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7): 406–415.10.1111/hiv.2012.13.issue-7
  • Monforte A, Anderson J, Olczak A. What do we know about antiretroviral treatment of HIV in women? Antivir Ther. 2013; 18(Suppl 2): 27–34.10.3851/IMP2647
  • Umeh OC, Currier JS. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol. 2006;2(2): 273–283.10.1517/17425255.2.2.273
  • Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153(6): 349–358.10.7326/0003-4819-153-6-201009210-00002
  • Monforte A, González L, Haberl A, et al. Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS. 2010;24(8): 1091–1094.10.1097/QAD.0b013e3283390db3
  • European AIDS Clinical Society (EACS). Guidelines version 8.1 English; 2016 October.
  • Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). Available at: https://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Revised November 13, 2014.
  • World Health Organization (WHO). Consolidation guidelines on HIV prevention, diagnosis, treatment and care for key populations; 2016.
  • Department of Health and Human Services (DHHS). Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States; 2014 March 28.
  • Johnson M, Walmsley S, Haberl A. A systematic review of the use of atazanavir in women infected with HIV-1. Antivir Ther. 2014;19(3): 293–307.10.3851/IMP2742
  • Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. The Lancet HIV. 2016;3: e410–e420.10.1016/S2352-3018(16)30016-9
  • Porter DP, Daeumer M, Thielen A, et al. Emergent HIV-1 drug resistance mutations were not present at low-frequency at baseline in non-nucleoside reverse transcriptase inhibitor-treated subjects in the STaR study. Viruses. 2015;7(12): 6360–6370.10.3390/v7122943
  • International Antiviral Society-USA (IAS-USA). Update of the drug resistance mutations in HIV-1. Available at: https://www.iasusa.org/content/drug-resistance-mutations-in-HIV. Accessed: February 2, 2017.
  • Varghese V, Liu TF, Rhee SY, et al. HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses. 2010;26(12): 1323–1326.10.1089/aid.2010.0123
  • DeJesus E, Rockstroh J, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379: 2429–2438.10.1016/S0140-6736(12)60918-0
  • Svarovskaia ES, Feng JY, Margot NA, et al. The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R Mutation. J Acquir Immune Defic Syndr. 2008;48(4): 428–436.10.1097/QAI.0b013e31817bbe93

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.